focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Hi Aber - I suppose the litmus test would be if any of the HNW investors feel the same. I imagine with their clout they could push for SP to be replaced if they felt the need.
You've got to concede that from our vantage point any view of the BoD is going to be fairly one-dimensional. It's easy, perhaps even lazy, to criticise our current position based on a few metrics such as measuring salaries against current sp. For all we know Tim wanted to raise funds via 'X' but Parker had to rein him in; we just don't know what gets discussed so unless the BoD are dumping their own shares like there's no tomorrow and 1801 is dead in the water, we have two options - carry on with gritted teeth or take a loss and move on.
I'm sure there are things Parker could do better (or worse, for that matter) but I have no idea what those things might be. So unless you have complete insider knowledge, be careful what you wish for.
Mysteries of the bleedin' universe, Potnak. I guess there are always competitors looking over your shoulder trying to get an advantage so with so much money potentially at stake, pharmas often keep quiet and only shout about successes.
At least we can console ourselves with the fact the internet cannot keep a secret - the truth will out!
Afternoon SOG - I think you're incorrect to suggest, "Licence not yet agreed as l would deem raising of finances a prior requisite" as that would seem to go against SAR's own website which notes, "...is now licensed to a private US-based bioharma company" and also the business weekly article that states, "...has signed a licence agreement for SRA737" so it would appear to be a done deal rather than still hanging in the balance.
https://sareum.com/research-development/#our-overview
https://www.businessweekly.co.uk/posts/sareum-shares-soar-as-it-starts-to-cash-in-on-cancer-programme
Sorry, Potnak, more detail here https://www.cambridgenetwork.co.uk/news/link-china-pharma-solutions-brokers-sareum-co-development-agreement-china-auroraflt3
Hi Potnak - it was Hebei Medical University Biomedical Engineering Center - http://www.chinabiotoday.com/articles/20131203_1
Hi SOG - the question is, if 737 is now with MEI, why the radio silence on it? What do they stand to gain in keeping it under wraps?
If Mei had licensed 737 they'd have had to announce it here within a day of signing the agreement - https://www.sec.gov/edgar/search/#/dateRange=1y&ciks=0001262104&entityName=MEI%2520Pharma%252C%2520Inc.%2520(MEIP)%2520(CIK%25200001262104)
Sorry, forgot to include this - https://otp.tools.investis.com/clients/uk/sareum_holdings_plc/rns/regulatory-story.aspx?cid=2841&newsid=1732138
Hi Andy - if the BoD sold any shares they'd have to RNS it - they RNS'd their options back in Nov - https://otp.tools.investis.com/clients/uk/sareum_holdings_plc/rns/regulatory-story.aspx?cid=2841&newsid=1730988
Hi Bobbler - I'm guessing OPUS couldn't finance us as it'd be a conflict of interest with SP involved in both companies.
Their plan might be to get as many 'bonus' shares as possible and just sit on them until we get a license deal then benefit massively.
No problem, I've been called worse ;-)
SOG?!?
Anyway, yes it also crossed my mind that it could be deliberately sidelined but surely a company could make more money in the long run by utilising 737.
For anyone still digging for info on who might have licensed 737, I think it's safe to say they are very private and not listed on the NASDAQ etc. If a company makes any deal that would affect their sp they have to notify the SEC and lodge details within 1 day here https://www.sec.gov/edgar/search/#
I searched for various terms that you might expect to find in the license agreement; SRA737, CRT Pioneer Fund or even "An additional fee made up of up to US$1.0 million cash and 500,000 shares" but no luck.
The closest I came was for an unrelated CRT PF deal - https://www.sec.gov/edgar/search/#/q=%2522CRT%2520Pioneer%2520Fund%2522&dateRange=custom&startdt=2023-01-01&enddt=2024-02-18
SRA737 gets mentioned by Acrivon Therapeutics but only as an example of competing CHK1 inhibitors - https://www.sec.gov/edgar/search/#/q=%2522SRA737%2522&dateRange=custom&startdt=2023-01-01&enddt=2024-02-18
We know there are plenty of reasearch papers all citing encouraging results using 737 so I find it strange that whoever now holds it is playing their cards very close to their chest. If it's been renamed we'll just have to look out for new CHK1 clinical trials.
Sierra are still operating as a subsidiary of GSK but are otherwise totally off the radar so anything in their pipeline is hidden from public view.
Regards.
Yeah Potnak, I understand where you're coming from but none of us know what RF's current holding is. For all we know their plan is to sell half to recoup some funds now but hold the other half for potentially much higher gains if a license deal comes along. If their business model is simply to sell their shares as soon as they get them then it doesn't provide much scope for making a profit if it tanks the sp in the process. Yes, they'll be handed more shares to make up any losses but I doubt their goal is simply to break even. RF's own share price is garbage so you'd think they'd be looking to invest (stop laughing at the back), in order to turn their own fortunes around.
Hi Laz - it would depend on who is buying the shares. Knowing P1a appears encouraging might suggest it's a buy and hold if an on-license is looking likely.
Another news article - https://www.businessweekly.co.uk/posts/sareum-says-so-long-to-sad-and-hi-to-happy-as-trials-hurdle-is-cleared
The company behind Krone's original post seem, uh, 'interesting' - https://en.wikipedia.org/wiki/BNN_Breaking
Yes, it's positive but it does have a whiff of AI generated text about it.